Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Ireland

Marie Skłodowska-Curie Action · Running

NO-CANCER-NET Advanced Engineering of Nitric Oxide Based Therapeutics for Triple Negative Breast Cancer Training Network

Coordinator
University of Galway, Ireland
Runs
1 October 2023 to 31 January 2028
Status
Running
EU funding
€2.7m
Total cost
—
Partners
20 organisations in 10 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101119873

What the project is doing

In the project's own words, from its summary on CORDIS.

NO-CANCER-NET will focus on Triple Negative Breast Cancer (TNBC) and Nitric Oxide (NO)-related therapeutic development. TNBC accounts for 10-20% breast cancers and is characterised by diagnosis at an early age and an aggressive phenotype. It indeed develops incurable distant metastasis within the first 2-3 years in approximately 30% patients. Despite significant efforts, TNBC treatment is limited to surgery and chemotherapy laying bare the urgent need for new targeted therapeutic development.

Our network has demonstrated an important role for inducible nitric oxide synthase (iNOS) and NO signalling in TNBC metastatic progression, with efficacy of iNOS targeting demonstrated in a phase I/II clinical trial of patients with distant metastasis. Based on NO’s yin/yang effect on tumour biology, iNOS/NO system can be targeted by either inhibiting iNOS and reducing the physiological levels of NO which drive tumour progression, or vice versa using NO donating drugs to increase NO to tumouricidal levels (similar to immune cells NO-mediated tumour targeting).

The NO-CANCER-NET Doctoral Network (DN) addresses two fundamental gaps in European training: 1) a network where a core of Doctoral Candidates (DCs) can share a basic understanding of molecular target discovery, models of tumour biology assessment, drug synthesis and delivery, developing diagnostics, handling complex spatial imaging and omics expression data profiles; and 2) solid interdisciplinary training in experimental, computational and clinical research.

NO-CANCER-NET will equip our DCs to understand the complexities of bench to bedside cancer research, the importance of an interdisciplinary approach and an understanding of the fundamentals of related disciplines. This will be of great importance in preparing DCs to work between academia, industry and in clinical healthcare providers.

Topics

Who is involved

OrganisationCityCountryRole
University of GalwayGalwayIrelandCoordinator
Association Hospitaliere De Bruxelles-Centre Hospitalier Universitaire Jules BordetAnderlechtBelgiumAssociatedpartner
3DBioFibR Inc.HalifaxCanadaAssociatedpartner
Inprother ApsKbenhavn NDenmarkAssociatedpartner
Kraeftens BekaempelseKoebenhavnDenmarkParticipant
Universidad De SevillaSevillaSpainParticipant
Ecole Pratique Des Hautes EtudesParisFranceParticipant
Galway Clinic Doughiska LimitedGalwayIrelandAssociatedpartner
Galway University HospitalGalwayIrelandAssociatedpartner
Royal College of Surgeons in IrelandDublin 2IrelandAssociatedpartner
The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near DublinDublinIrelandParticipant
Alma Mater Studiorum - Universita Di BolognaBolognaItalyAssociatedpartner
Consiglio Nazionale Delle RicercheRomaItalyParticipant
Innovamol SRLModenaItalyAssociatedpartner
Universita Degli Studi Di SienaSienaItalyParticipant
Universita Degli Studi Di UdineUdineItalyParticipant
Universite Du LuxembourgEsch-Sur-AlzetteLuxembourgParticipant
Catalyze B.V.Amsterdam-DuivendrechtNetherlandsAssociatedpartner
Houston Methodist HospitalUnited StatesAssociatedpartner
National Institutes of HealthBethesdaUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI